Get the Daily Brief
Latest Biotech News
Bayer Seals $1.3B Deal for KRAS G12D Cancer Drug – Trial Ready After IND
Bayer entered an exclusive global licensing and collaboration agreement with Kumquat Biosciences to develop and commercialize a KRAS G12D inhibitor, potentially worth over $1.3 billion. Kumquat...
Novartis Scores Twin Phase 3 Wins – Ianalumab Advances in Autoimmune Diseases
Novartis’ monoclonal antibody ianalumab achieved statistically significant results in two separate phase 3 studies targeting Sjögren’s syndrome and primary immune thrombocytopenia (ITP). This...
AI-Driven Precision Genome Editing – Deep Learning Designs Microhomology Templates
Researchers from the University of Zurich developed an artificial intelligence tool, Pythia, that predicts cellular DNA repair outcomes to improve precision genome editing. Combining deep learning...
Cancer Vaccine Nears Approval Despite Phase 3 Setback – IO Biotech Eyes FDA Talks
IO Biotech’s off-the-shelf cancer vaccine, Cylembio, narrowly missed the primary endpoint of progression-free survival in a phase 3 melanoma trial but showed encouraging data in patient subgroups...
Novel Protein-Based Antidote Emerges for Carbon Monoxide Poisoning
University of Maryland School of Medicine researchers engineered a breakthrough protein therapy that acts as a fast, selective antidote for carbon monoxide (CO) poisoning. Published in PNAS, the...
Rapid Oxygenated Macroencapsulation Sustains Insulin Cells for Diabetes Therapy
Cornell University researchers developed an oxygenated macroencapsulation system named BEAM that enables high-density transplant and survival of insulin-producing cells without immunosuppression...
AI and Data Analytics Propel Biopharma Monitoring and Coding Accuracy
Pharmaceutical companies are increasingly embracing data analytics and artificial intelligence (AI) to enhance clinical trial monitoring, compliance, and medical coding accuracy. Experts from Sage...
Decoding Cold Sores: Host Enzyme Targeted to Prevent HSV-1 Latency
A team led by Esther González-Almela at Guangdong Academy of Medical Sciences revealed that herpes simplex virus type 1 (HSV-1) hijacks host enzymes RNA polymerase II and topoisomerase 1 (TOP1)...
FDA Clears First DPP1 Inhibitor for Bronchiectasis Treatment – Insmed’s Brinsupri Launches
The U.S. FDA granted approval for Insmed’s Brinsupri (brensocatib), marking the first treatment for non-cystic fibrosis bronchiectasis (NCFB). This oral DPP1 inhibitor targets neutrophilic...
Bayer Joins Kumquat in $1.3B Race to Target KRAS G12D Mutation in Cancer
Bayer has entered a collaboration with Kumquat Biosciences to develop Kumquat’s investigational KRAS G12D inhibitor for pancreatic, colorectal, and lung cancers. The deal could deliver over $1.3...
AI and Deep Learning Propel Genome Editing Precision with Deep-Learning Design
Researchers at the University of Zurich have developed 'Pythia,' an AI tool that predicts cellular DNA repair outcomes post-CRISPR editing to design microhomology-based DNA repair templates. This...
Generative AI Designs Small Enzymes for Enhanced Bioprocessing Efficiency
Scientists led by Hiroyuki Hamada at Kyushu University have leveraged ProtGPT2, a protein language model, to design smaller, novel variants of malate dehydrogenase enzymes for bioprocessing. This...
Cancer Vaccine for Melanoma Narrowly Misses Phase 3 Endpoint but Eyes FDA Pathway
IO Biotech’s off-the-shelf cancer vaccine, Cylembio, combined with Merck’s Keytruda narrowly failed to achieve statistically significant progression-free survival in a pivotal phase 3 trial for...
Novartis Scores Multiple Phase 3 Wins in Autoimmune Diseases with Ianalumab
Novartis announced positive results from two Phase 3 studies of its B-cell depleting antibody, ianalumab, in Sjögren’s syndrome and primary immune thrombocytopenia (ITP). Both trials achieved...
AI Innovations Accelerate Cell Therapy Manufacturing and Clinical Predictions
Partnerships and studies illustrate AI’s expanding role in biotech: Sartorius Stedim Biotech and Nanotein Technologies collaborate to boost immune cell expansion for cell therapy applications via...
FDA Regulatory Movements and Leadership Shakeups Shape Biotech Landscape
The FDA approved Boehringer Ingelheim’s oral HER2-targeted drug Hernexeos for non-small-cell lung cancer, accompanied by clearance of Oncomine Dx Target Test as its companion diagnostic....
New Protein Therapy Offers Potential Antidote for Carbon Monoxide Poisoning
University of Maryland School of Medicine researchers engineered a novel protein-based antidote demonstrating promising efficacy in rapidly removing carbon monoxide with fewer adverse effects...
PureTech Spins Out Lung Disease Drug to New Subsidiary Celea Therapeutics
PureTech Health has launched Celea Therapeutics to advance its drug candidate deupirfenidone (LYT-100) targeting idiopathic pulmonary fibrosis (IPF) and other inflammatory lung diseases....
Pfizer’s Padcev Shows Survival Benefit in Bladder Cancer with Keytruda Combo
Pfizer reported positive early data from a bladder cancer trial combining its antibody-drug conjugate Padcev with Merck’s Keytruda. The combo extended event-free survival and overall survival in...
Novartis Secures Multiple Phase 3 Wins with Antibody Ianalumab in Autoimmune Diseases
Novartis announced positive Phase 3 results for its B cell-targeting antibody ianalumab in Sjögren’s syndrome and primary immune thrombocytopenia (ITP). Both large registrational trials...